The diagnostic criteria for antibody-mediated rejection (ABMR) after small bowel transplantation (SBT) are not clearly defined, although the presence of donor-specific antibodies (DSAs) has been reported to be deleterious for graft survival. We aimed to determine the incidence and prognostic value of DSAs and C4d in pediatric SBT and to identify the histopathologic features associated with C4d positivity. We studied all intestinal biopsies (IBx) obtained in the first year posttransplantation (N = 345) in a prospective cohort of 23 children. DSAs and their capacity to fix C1q were identified by using Luminex technology. Eighteen patients (78%) had DSAs, and 9 had the capacity to fix C1q. Seventy-eight IBx (22.6%) were C4d positive. The independent determinants of C4d positivity were capillaritis grades 2 and 3 (odds ratio [OR] 4.02, P = .047 and OR 5.17, P = .003, respectively), mucosal erosion/ulceration (OR 2.8, P = .019), lamina propria inflammation grades 1 and 2/3 (OR 1.95, P = .043 and OR 3.1, P = .016, respectively), and chorion edema (OR 2.16, P = .028). Complementfixing DSAs and repeated C4d-positive IBx were associated with poor outcome (P = .021 and P = .001, respectively). Our results support that capillaritis should be considered as a feature of ABMR in SBT and identify C1q-fixing DSAs and repeated C4d positivity as potential markers of poor outcome.
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| INTRODUC TI ON

Small bowel transplantation (SBT) is indicated in patients with total
and irreversible intestinal failure, together with complications of parenteral nutrition. Considerable progress has been made during the past several decades, with the development of new immunosuppressive drugs and improvements in surgical techniques. However, several factors, such as acute rejection, infections, and lymphoproliferative disorders, still impair graft and patient survival, with a 60% 5-year patient survival rate and a 5-year graft survival rate of <50%, and most of the graft losses occurring during the first year. 1, 2 In recent years, the use of the Luminex sensitive techniques to detect donor-specific anti-HLA antibodies (DSAs) has allowed antibody-mediated rejection (ABMR) to be increasingly recognized in solid organ transplantation. ABMR is a major cause of allograft loss in heart and kidney transplantation. 3, 4 Recently, ABMR has also been identified as an important issue in SBT, and its implication in the poor graft survival after SBT is increasingly suspected.
Several groups have shown that the presence of DSAs was associated with a worse outcome [5] [6] [7] and with a higher risk of rejection. [8] [9] [10] Abu-Elmagd et al 11 reported the role of DSAs in 194 SBT recipients and showed that preformed DSAs were associated with an increased risk of acute rejection, whereas de novo DSAs were associated with a risk of graft loss and chronic rejection. However, the pathology of ABMR in SBT is not currently defined and is not taken into account in the current classification system of rejection in SBT 12 (Table S1 ). Vascular alterations, including capillary dilatation and congestion, edema, erythrocyte extravasation, and vasculitis, have been reported to be associated with high panel reactive antibodies.
11,13
The aims of this study were to determine the incidence and prognostic value of DSAs and C4d in pediatric SBT and to identify the histopathologic features associated with C4d positivity. To address these questions, we studied a cohort of pediatric small bowel recipients with analysis of all intestinal biopsies performed in the first year posttransplantation with systematic C4d staining and evaluation of DSAs, capacity to fix C1q, and outcome. We found a high incidence of DSAs and C4d positivity in our pediatric population and identified capillaritis, mucosal erosion/ulceration, lamina propria inflammation, and chorion edema as independent determinants of C4d positivity. Complement fixing capacity of DSAs and repetition of C4d-positive (C4d + ) biopsies were associated with poor outcome.
| PATIENTS AND ME THODS
| Population
We included all children who were transplanted in our institution 
| Study design
| Immunosuppression
Immunosuppression relied on the administration of prednisone and tacrolimus. Interleukin-2 receptor antagonist (basiliximab) induction was used in all patients, except in the 4 patients with repeat transplantation, in whom an intravenous dose (5 mg/kg) of rabbit antithymocyte globulin (Thymoglobulin; Genzyme, Lyon, France) for 5 days was used.
The 12-hour tacrolimus trough levels during the first 3 months were targeted at 12 to 15 ng/mL and then tapered to 8 to 10 ng/ mL.
Acute allograft rejection episodes were treated with high-dose corticosteroids. In the presence of DSAs, plasma exchanges were performed 5 times, followed by IVIg (2 g/kg).
| Detection of DSAs
All assays were performed as recommended by the manufacturers, . Posttransplantation sera were drawn every week in the first 2 months and then once per month. Sensitization was also detected by using the Luminex screening assay, and positive sera were analyzed by using SAFB assays for class I and/or class II HLA.
The antibody positivity threshold was set at a normalized mean fluo- 
| Pathology
IBx were fixed in formalin and stained with hematoxylin-eosin for routine microscopy.
Only adequate IBx were included in the statistical analysis. A summary of the definitions of the histologic lesions is given in Table S2 .
Intestinal T cell-mediated rejection (TCMR) was diagnosed and graded from undetermined to severe based on the scheme proposed at the VIIIth International Small Bowel Transplant Symposium 12 (Table S1 ).
| C4d staining
Immunohistochemical C4d staining was performed on all adequate protocol or indication biopsies, on paraffin-embedded tissue sections using monoclonal rabbit anti-human C4d antibody (DB-107, Positive controls were renal allograft biopsies with documented ABMR or ABO incompatible renal allografts. Negative controls were normal IBx. A control group of patients with inflammatory bowel disease (n = 10) was also tested for C4d staining (data not shown), with a negative C4d for all the biopsies.
| Follow-up
The median follow-up period post SBT was 3.8 years (IQR 0.75-5.63 years), ranging from 43 days to 6.82 years. IBx were studied during the first year post SBT. Graft and patient survival rates were reported.
| Statistical analysis
We 
| RE SULTS
| Population
Twenty-three patients (14 boys) received an SBT from an ABO blood type-identical deceased donor, and this was combined with a liver in 9 cases or with multivisceral transplantation in 2 cases. Four patients received a second SBT.
The characteristic demographic data and clinical features are summarized in Table 1 . The mean recipient age was 6.6 ± 3.7 years and ranged from 1.1 to 16.2 years. The main cause of intestinal failure was congenital enteropathy (microvillous inclusion disease or tufting enteropathy) in 52.2% of the patients, followed by short bowel syndrome in 7 patients (30.4%) and motility disorder in 4 patients (17.4%).
All patients received red blood cell (RBC) infusions on the day of transplantation (mean 3.4 ± 2.6, range 1-11 infusions) and all but 6 patients received RBC infusions during the first month posttransplant (mean 5.5 ± 4.7). At least 7 patients received RBC and platelet infusions before transplantation; information was not available for the other patients.
| DSAs
The characteristics of DSAs are summarized in Table S3 .
| Histologic parameters associated with positive C4d
A total of 440 IBx performed during the first year post SBT were reviewed, and 345 adequate IBx were included in the analysis (mean 15 ± 5 per patient). Ninety percent of the IBx were performed during the first 3 months. The detailed pathology findings are reported in graded as mild rejection (9.6%), 21 were graded as moderate rejection (6.1%), and 22 were graded as severe rejection (6.4%).
In a comparison of the histology of C4d + and C4d -IBx (Table 3) ,
C4d
+ IBx were performed significantly earlier (28.2 ± 28.2 vs 51.1 ± 66.6 days, P = .011) and were associated with significantly more histologic features of rejection (apoptosis, P < .0001; lamina propria inflammation, P < .0001; crypt necrosis, P = .001; and mucosal erosion/ulceration P < .0001). Capillaritis and thrombosis were also found more frequently in C4d + IBx (P < .0001 and P = .005, respectively). According to ISBTS classification, rejection episodes in C4d + IBx were significantly more severe than in C4d -IBx (P < .0001).
Thirty-nine percent of biopsies with TCMR (including mild, moderate, and severe TCMR, n = 76) showed C4d positivity (n = 30).
| Determinants of C4d positivity
Seven histologic parameters were independently associated with positive C4d staining after univariable analysis (mucosal erosion/ ulceration, capillaritis, lamina propria inflammation, gland necrosis, thrombosis, apoptosis, and chorion edema; P < .2, Table 4 propria inflammation grades 2/3 and 1 (OR 3.10 and 1.95, P = .016 and .043, respectively), mucosal erosion/ulceration (OR 2.80, P = .019), and chorion edema (OR 2.16, P = .028). Liver transplantation was of borderline significance, with an OR of 0.56 (P = .051) ( Table 4) .
| Kinetics and association of C4d positivity with the 4 histologic parameters (capillaritis, lamina propria inflammation, mucosal erosion/ulceration, and chorion edema)
We studied the relationship among the 4 histologic features significantly associated with C4d positivity from the multivariable analysis. The conditional density plot in Figure 2 Table S4 ). Capillaritis was graded as 2 separate scores that were merged as a unique grade for analysis purposes. The E score ("Extent') evaluated the percentage of the area with microvascular inflammation in capillaries, with a score 0 representing <10% of MI and a score 1 representing >10% of MI on the area. The C score ("Cellularity") evaluated the maximal number of cells in the most affected capillary, with a score of 0 indicating 0-2 cells in the capillary, a score of 1 indicating 3 or 4 cells in the capillary, and a score of 2 indicating >5 cells in a capillary. The composite score was defined as follows: E0C0 (grade 0), E0C1 + E0C2 (grade 1), E1C1 (grade 2), and E1C2 (grade3).
TA B L E 3 Histologic and immunologic characteristics according to the C4d status (<2 vs ≥2)
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TA B L E 4
We compared the 2-year graft/patient survival rates among patients with <15% of C4d + IBx (n = 8), 15% to 30% of C4d
Patients with <15% of C4d + IBx had a better survival (87.5% at 2 years) compared with patients with 15% to 30% of C4d + IBx (75% at 2 years) and patients with >30% of C4d + IBx (14.3% at 2 years, log-rank test, P = .001) ( Figure 3A) . Patients with >30% of C4d + IBx (n = 7) displayed a significantly higher percentage of IBx with mucosal erosion/ulceration, capillaritis, and lamina propria inflammation 
| D ISCUSS I ON
Relying on a large number of IBx from a series of pediatric recipi- Estimates were obtained using the Kaplan-Meier method and compared using the log-rank test. B. Graft and patient survival analysis according to the presence of DSA and to the capacity of DSA to fix C1q. Estimates were obtained using the Kaplan-Meier method and compared using the log-rank test
also an important criterion of ABMR after kidney, heart, pancreas, and liver transplantation, 14, 15 and our results suggest that this is also De novo DSAs and persistent preexisting DSAs have been associated with a significantly worse survival compared with patients with no DSAs or patients with preformed DSA dropping to undetectable levels after SBT. 11 In our pediatric cohort, DSAs were found in a high percentage of patients (87.0%) either preformed (35%) or early de novo (65%), with a class II iDSA in 65% of DSA+ patients, which is higher than previously described. 18, 19 The high incidence of DSAs in our cohort may be in part explained by the induction therapy consisting only of basiliximab in most patients compared with rabbit antithymocyte globulin or alemtuzumab in the other studies 20 and by the high rate of RBC transfusion.
Interestingly, in our study, the C1q-fixing capacity of the DSAs was associated with a poorer 2-year graft survival compared with DSAs with no C1q-fixing capacity, as previously reported in kidney transplantation. 21 Finally, we found that the repetition of C4d positivity,
as assessed by the percentage of C4d + IBx, was associated with a poor prognosis. As expected, the incidence of edema, capillaritis, erosion/ulceration, and lamina propria inflammation increased with the percentage of C4d + IBx, but the size of our series did not allow us to build reliable models to investigate an independent role of histopathology on graft survival. 
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